Version 1
: Received: 3 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (15:33:23 CET)
How to cite:
Mavritsakis, N.; Șușan, R. M.; Șușan, M. M.; Groza, G. G.; Ursu, V. E.; Rusu, R. G.; Boariu, D.; Ionescu, E.; Muntean, R. I.; Man, C. M. Epidemiology, Clinical Manifestations, and Management of Prolactinomas: A Comprehensive Study. Preprints2024, 2024020277. https://doi.org/10.20944/preprints202402.0277.v1
Mavritsakis, N.; Șușan, R. M.; Șușan, M. M.; Groza, G. G.; Ursu, V. E.; Rusu, R. G.; Boariu, D.; Ionescu, E.; Muntean, R. I.; Man, C. M. Epidemiology, Clinical Manifestations, and Management of Prolactinomas: A Comprehensive Study. Preprints 2024, 2024020277. https://doi.org/10.20944/preprints202402.0277.v1
Mavritsakis, N.; Șușan, R. M.; Șușan, M. M.; Groza, G. G.; Ursu, V. E.; Rusu, R. G.; Boariu, D.; Ionescu, E.; Muntean, R. I.; Man, C. M. Epidemiology, Clinical Manifestations, and Management of Prolactinomas: A Comprehensive Study. Preprints2024, 2024020277. https://doi.org/10.20944/preprints202402.0277.v1
APA Style
Mavritsakis, N., Șușan, R. M., Șușan, M. M., Groza, G. G., Ursu, V. E., Rusu, R. G., Boariu, D., Ionescu, E., Muntean, R. I., & Man, C. M. (2024). Epidemiology, Clinical Manifestations, and Management of Prolactinomas: A Comprehensive Study. Preprints. https://doi.org/10.20944/preprints202402.0277.v1
Chicago/Turabian Style
Mavritsakis, N., Raul Ioan Muntean and Cristina Maria Man. 2024 "Epidemiology, Clinical Manifestations, and Management of Prolactinomas: A Comprehensive Study" Preprints. https://doi.org/10.20944/preprints202402.0277.v1
Abstract
This research delves into the epidemiology, clinical manifestations, and management of hyperprolactinemia, particularly focusing on prolactin-secreting pituitary adenomas, or prolactinomas, in Dolj County, a region historically underrepresented in medical literature. Hyperprolactinemia, a prevalent endocrine disorder, arises from excessive prolactin secretion by the pituitary gland's lactotrope cells and presents a diverse clinical picture. The most significant etiological contributors identified are prolactinomas, accounting for approximately 39% of all secretory pituitary tumors.
In light of hyperprolactinemia's substantial morbidity and prevalence, this study underscores the necessity of comprehensive understanding of its regional epidemiology and clinical presentations. Our methodology incorporated collecting retrospective data across various medical facilities in Dolj, ensuing a meticulous analysis of clinical features, paraclinical investigation outcomes, and therapeutic responses among patients with prolactinomas. Emphasis was placed on discerning risk factors, demographic characteristics, and associated comorbidities to encapsulate the full spectrum of these tumors' impact within the community.
Preliminary results suggest a nuanced incidence rate of prolactinomas within Dolj, with specific demographic and clinical trends potentially distinct from those reported in wider literature. These findings stress the critical role of localized studies in enhancing screening, diagnostic, and therapeutic protocols. Ultimately, this investigation offers critical insights into the epidemiology and symptomatology of prolactinomas in Dolj, significantly augmenting existing literature and informing regional medical practices.
Keywords
pituitary tumor; hyperprolactinemia; amenorrhea
Subject
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.